All Trials

A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label single-arm study for adults with previously untreated transformed SCLC arising after EGFR-mutated NSCLC treated with an EGFR TKI, requiring measurable disease and ECOG 0–1. Participants receive PF-08634404/SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF, with chemotherapy followed by PF-08634404 maintenance.

ClinicalTrials.gov ID: NCT07476287

A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ER-positive/HER2-negative metastatic or locoregionally recurrent breast cancer progressing after prior systemic therapy including a CDK4/6 inhibitor receive oral camizestrant, an ER-degrading SERD, plus oral atirmociclib, a CDK4-selective cell-cycle inhibitor. Eligible patients have ECOG 0–1 and RECIST-assessable disease.

ClinicalTrials.gov ID: NCT07427394

Phase 2 Trial With a Safety Run-in of Combinatorial Therapies With Intrathecal (IT) Dendritic Cell Vaccines (cDC1s) inHER+ (Combined With IT Trastuzumab) and HER2- (Combined With IT Nivolumab) Breast Cancer (BC) Leptomeningeal Disease (LMD)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HER2-positive or HER2-negative breast cancer and confirmed leptomeningeal disease receive an intrathecal autologous cDC1 vaccine designed to induce HER2/HER3-specific T-cell responses. HER2-positive patients also receive intrathecal trastuzumab (HER2-targeted), while HER2-negative patients receive intrathecal nivolumab (PD-1 blockade).

ClinicalTrials.gov ID: NCT07694986

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 metastatic KRAS G12D-mutated colorectal adenocarcinoma receive oral VS-7375, a KRAS G12D ON/OFF inhibitor, alone or with cetuximab/panitumumab after progression on ≥1 metastatic regimen. Treatment-naïve first-line patients receive VS-7375 plus cetuximab and mFOLFOX6.

ClinicalTrials.gov ID: NCT07659795

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For previously treated, locally advanced or metastatic MUC16-positive, SMARCB1-deficient renal medullary carcinoma/renal cell carcinoma with medullary phenotype or epithelioid sarcoma. Patients receive ubamatamab, a MUC16×CD3 T-cell–redirecting bispecific antibody, alone with the option to add the anti-PD-1 antibody cemiplimab after progression, or in combination.

ClinicalTrials.gov ID: NCT06444880

An Open-Label Phase II Study of ILKN421H in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1, unresectable locally advanced or metastatic squamous or nonsquamous NSCLC without actionable EGFR/ALK/ROS1 alterations are eligible either after progression on PD-1/PD-L1 therapy regardless of PD-L1 status or untreated with PD-L1 TPS ≥1%. Patients receive pembrolizumab plus ILKN421H, an mRNA therapy encoding an albumin-fused, IL-2Rβ/γ-selective IL-2 variant designed to expand CD8 T and NK cells while avoiding IL-2Rα signaling.

ClinicalTrials.gov ID: NCT07452224

A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 unresectable advanced/metastatic non-squamous NSCLC harboring EGFR mutations or ALK/ROS1/RET/NTRK fusions after progression on appropriate targeted therapy receive ivonescimab, a bispecific PD-1/VEGF-A antibody, alone if previously treated with platinum/pemetrexed. Chemotherapy-naive patients with ALK/ROS1/RET/NTRK fusions receive ivonescimab plus carboplatin/pemetrexed followed by ivonescimab/pemetrexed maintenance; prior checkpoint inhibitor therapy is not allowed.

ClinicalTrials.gov ID: NCT07405190

A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with stage IV non-squamous NSCLC, ECOG 0–1, progressing after ≥12 weeks of pembrolizumab-based therapy and prior platinum chemotherapy, with an injectable thoracic lesion, are randomized to continued pembrolizumab plus intratumoral CAN-2409 and oral valacyclovir or docetaxel. CAN-2409 is a nonreplicating adenoviral vector encoding HSV thymidine kinase that activates valacyclovir metabolites to induce tumor-cell death and systemic antitumor immunity.

ClinicalTrials.gov ID: NCT07660094

A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic KRAS G12D-mutated NSCLC, ECOG 0–1, who progressed after platinum chemotherapy and anti–PD-1/PD-L1 therapy are randomized to IV setidegrasib or docetaxel. Setidegrasib is a KRAS G12D-selective protein degrader that recruits VHL E3 ligase to drive mutant KRAS degradation.

ClinicalTrials.gov ID: NCT07566052

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic KRAS G12D-mutated pancreatic ductal adenocarcinoma and ECOG 0–1 are treated in the first- or second-line setting. Patients receive oral VS-7375, a dual-state KRAS G12D inhibitor, alone or with the anti-EGFR antibody cetuximab.

ClinicalTrials.gov ID: NCT07644559